Single User License
INR 236460
Site License
INR 472920
Corporate User License
INR 709380

Service Tax Additional

select a format
Price

Single User License
USD 3500
Site License
USD 7000
Corporate User License
USD 10500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)-Pipeline Review, H2 2016

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)-Pipeline Review, H2 2016', provides in depth analysis on Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted pipeline therapeutics.

The report provides comprehensive information on the Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)

The report reviews Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics and enlists all their major and minor projects

The report assesses Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) Overview 6

Therapeutics Development 7

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)-Products under Development by Stage of Development 7

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)-Products under Development by Therapy Area 8

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)-Products under Development by Indication 9

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)-Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)-Products under Development by Companies 12

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)-Products under Development by Universities/Institutes 14

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)-Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 19

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)-Companies Involved in Therapeutics Development 21

Conatus Pharmaceuticals Inc. 21

LG Life Science LTD. 22

New World Laboratories, Inc. 23

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)-Drug Profiles 24

ED-11-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

emricasan-Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

nivocasan-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

NWL-154-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Small Molecules to Inhibit Caspase 3 and Caspase 6 for Huntington's Disease-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)-Dormant Projects 34

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)-Featured News & Press Releases 36

May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial 36

Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data 37

Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting 38

Feb 03, 2016: FDA Grants Conatus Fast Track Designation for Development of Emricasan in NASH Cirrhosis 38

Jan 11, 2016: Conatus Initiates Phase 2b ENCORE-NF Clinical Trial of Emricasan in Patients With NASH Fibrosis 38

Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial 39

Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting 41

Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting 41

Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting 42

Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting 42

Sep 23, 2015: Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis 43

Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement 44

Apr 23, 2015: Conatus Clinical Results at EASL Meeting Support Emricasan Registration Pathway in NASH 45

Apr 08, 2015: Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting 47

Apr 08, 2015: Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting 48

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 19

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by Conatus Pharmaceuticals Inc., H2 2016 21

Pipeline by LG Life Science LTD., H2 2016 22

Pipeline by New World Laboratories, Inc., H2 2016 23

Dormant Projects, H2 2016 34

Dormant Projects (Contd..1), H2 2016 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Conatus Pharmaceuticals Inc.

LG Life Science LTD.

New World Laboratories, Inc.

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) Therapeutic Products under Development, Key Players in Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) Therapeutics, Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) Pipeline Overview, Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) Pipeline, Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com